Treats Attention Deficit Hyperactivity Disorders (ADHD) and Narcolepsy. ANDA 208737, held by Cediprof. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 208737 (Methylphenidate Hydrochloride), held by Cediprof, was first approved by FDA on Feb 1, 2019, with 2 approved supplements and 0 published complete response letters.
Methylphenidate hydrochloride tablets are indicated for the treatment of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 1, 2019 | Original application | Approved | None posted |
| Methylphenidate Hydrochloride5MG · tablet;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride10MG · tablet;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride20MG · tablet;oral | Methylphenidate Hydrochloride | Rx |
| Apr 1, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Dec 16, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 1, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters